Learn about IHI during our session on rare diseases
IHI session: ‘Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration’
Wednesday 5 June, 11:00 – 12:00 | Room 26A
IHI organised a session in the Orphan and Rare Disease track of the BIO programme. There are over 7,000 identified rare diseases, and while each of these is by definition rare, collectively they affect more than 300 million people globally, or around 4% of the world’s population. Yet just a fraction of rare diseases has an approved therapy, and efforts to develop safe, effective therapies are hampered by issues such as the tiny numbers of patients involved and our poor understanding of many rare diseases. This session featured collaborative research model case studies on rare and orphan diseases from both sides of the Atlantic that are making practical contributions to the advancement of research and drug development in this highly challenging field.
Meet the speakers
- Niklas Blomberg, Executive Director, Innovative Health Initiative (IHI) (moderator)
- Annette Bakker, PhD, President, Children's Tumor Foundation
- Claire Skentelbery, Director General, EuropaBio
- Deborah Requesens, PhD, Director, JumpStart Program, Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
- Klaus Romero, MD, Chief Executive Officer, Chief Science Officer, Critical Path Institute
Hear from IHI speakers during other sessions
Session: 'Strengthening of the Clinical Trials Environment in Europe Under the Accelerating Clinical Trials (ACT EU) Initiative'
Tuesday 4 June, 11:00 - 12:00 | Room 31C
IHI Senior Scientific Project Manager Nathalie Seigneuret spoke at this session on ACT EU, which is part of the Clinical Trials Innovations track.
Session: 'The Promise of Personalized Treatment Becoming Reality: How INT Could Change Oncology'
Wednesday 5 June, 15:00-16:00 | Room 26A
IHI Executive Director Niklas Blomberg was a speaker at a session on INT (individualised neoantigen treatment) therapies which is part of the Oncology track.
About BIO
The BIO International Convention (BIO) attracts 16 000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The programme includes a strong educational programme with over 150 sessions addressing cutting-edge issues in a wide spectrum of life science and application areas. The event exhibition features over 1 800 exhibitors including several international pavilions.
To find more about about BIO, visit the event website.